Laser Therapy Devices Market Size, Share, Analytical Overview, Growth Factors, Demand, Trends and Forecast to 2031

Future Market Insights’ (FMI) latest report on the global laser therapy devices market expects a healthy growth trend, reach a value of almost US$ 2 billion by 2022, registering a CAGR of around 4%. Long-term prospects also appear bright, with numerous large-scale investments underway to adopt laser treatment procedures, amid rising inclination towards minimally invasive surgeries.

As per FMI’s analysis, oncology and aesthetics treatment are expected to emerge as key growth engines, followed by ophthalmology applications. Furthermore, preference for low level laser therapy (LLLT) is expected to increase, prompting key manufacturers to introduce a slew of innovative laser therapy devices solutions in the long-run. In 2019, the US Food & Drug Administration approved the Erchonia FX 635, a LLLT device to address whole-body pain, reducing the incidence by nearly 50%.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5241

According to the Cancer Atlas, there were an estimated 18.1 million active cases, with over 9 million cancer deaths in 2018. Additionally, nearly 44 million individuals persons living with cancer that same year who were diagnosed within the previous’ five years. It is projected that this burden is expected to rise by over 60% by 2040. Hence, credible progress is expected to be made in this regard.

Key Takeaways from FMI’s Laser Therapy Devices Market Study

By device type, gas laser therapy devices to account for more than a quarter of the revenue share through 2021
A fifth of the total laser therapy devices revenue is accounted for by hospitals, specialty clinics to generate over half of the total share
Ophthalmology treatment is likely to account for the bulk of the revenue share in the laser therapy devices market
US and UK to experience high sales amid surging popularity of low-level laser therapy (LLLT)
High prevalence rates of dermatological disorders to fuel laser therapy device sales across Germany
Robust healthcare research funding and a flourishing aesthetics industry to pivot French laser therapy devices market growth
High plastic surgery rates to heighten China’s share in the laser therapy devices market
“Prominent laser therapy devices manufacturers are introducing portable handheld devices in order to enhance the comfort factor for surgeons while administering the appropriate treatment, improving patient outcomes and success rates,” says the FMI analyst.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-5241

Competitive Landscape

Boston Scientific Corporation, IPG Photonics Corporation, Lumenis Ltd., Coherent Inc., Biolitec AG, Hologic Inc., Alma Lasers Ltd., Fotona D.D, Danaher Corporation and Thermo Fisher Scientific Inc. are some prominent laser therapy devices manufacturers as profiled by FMI’s report. New product launches, capacity expansion initiatives and securing regulatory approvals for specific techniques are some key growth strategies.

In 2018, Hologic Inc. received a medical device license issued by Health Canada to market Cynosure’s advanced non-invasive body contouring product called SculpSure®, a laser treatment device for treating back, inner and outer thighs, and submental area under the chin. This approach destroys fat cells by raising body fat temperature.

Recently, in April 2021, Alma Lasers Ltd. launched the Alma PrimeXTM platform, a non-invasive approach for body contouring and skin tightening in the abdomen, waist, thighs and buttock areas. It deploys a combination of ultrasound and radiofrequency technologies.

More Insights on the Global Laser Therapy Devices Market

In its latest report, FMI offers an unbiased analysis of the global laser therapy devices market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of device type (solid-state laser, gas laser, liquid laser and semiconductor laser), end-user (hospitals, ambulatory surgical centers, specialized clinics and other end-users), application (ophthalmology, dermatology, gynecology, dentistry, urology, cardiovascular and others) and region (North America, Latin America, Europe, Japan, APEJ and Middle East & Africa).

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/5241

Key Segments Covered Device Type

Solid-State Laser
Gas Laser
Liquid Laser
Semiconductor Laser
End-User

Hospitals
Specialized Clinics
Ambulatory Surgical Centers
Other End-Users
Application

Ophthalmology
Dermatology
Gynecology
Urology
Cardiovascular
Others

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Sports Medicine Market is projected to reach a valuation of US$ 6.8 Billion in 2022

[210 Pages Report] Demand for sports medicines is gaining traction as the sports industry is getting back on track after a temporary period of lull, following the COVID-19 outbreak. According to a study by Future Market Insights, the market will showcase recovery 2021 onwards, a trend which is expected to result in accelerating sales through 2031.

As the requirement for sports medicines for various types such as body reconstruction, body monitoring & evaluation, and others is rising again, the market is projected to record robust growth in the coming years. The latest revised edition of the report on ‘sports medicine’ market study by Future Market Insights (FMI) offers a thorough analysis of the global trends, demand-supply trajectories, and growth & restraining factors for sports medicine suppliers during the forecast period of 2021 to 2031.

According to the report, knee & shoulder injuries will account for the increasing sales of sports medicine while the focus of manufacturers will be on the leading regions such as North America, Europe, and Asia Pacific.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-5173

Key Takeaways from Market Study

  • The global sports medicine market is forecast to expand at over 7.5% CAGR through 2031
  • High demand for body reconstruction and body support & recovery type of sports medicine to fuel the sales
  • Rise in application in knee, shoulder, and ankle & foot injuries to cater to the growth of manufacturers
  • The United States to maintain its lead in the world’s largest sports medicine industry North America
  • Germany remains dominant in Europe sports medicine industry
  • Asia Pacific to emerge a highly lucrative market for sports medicine with its epicenters in China and India
  • Japan, the United Kingdom, Canada, France, Italy, and a few other countries to maintain positive market outlook

“Companies operating in the sports medicines market are focusing on innovations and product launches, besides aiming for certifications from international organizations. There is increasing focus on keeping pace with changing consumer preferences” says an FMI analyst.

Knee & Shoulder Injuries Fuelling Sports Medicines SalesRise in application of body reconstruction, body recovery, and other type of sports medicine in knee & shoulder injuries is becoming prominent around the globe. This in turn is set to raise the profit margins of suppliers in the near future.

According to the National Health Statistics Report published on 18th November, 2016, an average annual estimate of 8.6 million sports and recreation related injuries were reported among which knee & shoulder injuries were of the highest number. As stated in the report, one-half of the injury episodes resulted in treatment at a doctor’s office or health clinic while rest half needed emergency care or hospitalization. These figures represent why this segment is gaining momentum in terms of application.

Who is Winning?The global sports medicine market is fragmented and thriving on the key players. In order to sail through the cut-throat competition, key players are launching diverse range of cost-effective products and services. For instance,

  • Breg Inc. launched its new brand for Orthopedic Service Lines which include OrthoSelect® Consulting, BregBill Programs, Breg Vision® Software, and others on 7th March, 2018
  • Medtronic Plc. launched its new range of Spinal and Orthopaedic Products and solutions such as T2 Stratosphere, Electrosurgical Products, and others a couple of years back

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-5173

More Valuable InsightsIn its latest report, FMI offers an unbiased analysis of the sports medicine market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product type (body reconstruction, body support & recovery, body monitoring & evaluation, and accessories), and application (knee injuries, shoulder injuries, ankle & foot injuries, back & spine injuries, elbow & wrist injuries, hip injuries, and other applications), across seven major regions of the world (North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA).

Sports Medicine Market – Market Segmentation by CategoryProduct Type

  • Body Reconstruction
  • Body Support and Recovery
  • Body Monitoring and Evaluation
  • Accessories

Application

  • Knee Injuries
  • Shoulder Injuries
  • Ankle & Foot Injuries
  • Back & Spine Injuries
  • Elbow & Wrist Injuries
  • Hip Injuries
  • Other Applications

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-5173

Region

  • North America
  • Latin America
  • Europe
  • Middle East and Africa (MEA)
  • East Asia
  • South Asia
  • Oceania

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Herbal Medicinal Products Market is expected to reach US$ 360.35 Billion by the end of 2031

The herbal medicinal products market revenue totaled US$ 171.62 Bn in 2021, according to Future Market Insights (FMI) study. The overall sales of herbal medicinal products is expected to reach US$ 360.35 Bn by 2031, growing at a CAGR of 7.7 % for 2021 – 2031.

Government initiatives undertaken around the world, especially in the West to encourage the use of herbal medicine has resulted in the development of mass distribution networks, increasing prescription of homeopathic medications, and demand for Ayurveda treatments.

According to a recent study by Future Market Insights (FMI), these factors have proven crucial at enabling growth in the herbal medicinal market. Sales of herbal medicines are expected to top US$ 171.62 Bn in 2021, at a CAGR of 7.7% during the forecast period (2021-2031).

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2722

Soaring concerns pertaining to adverse effects of allopathic medicines has been causing gradual shift of preference in favor of traditional herbal medicines. These medicines are often used for treatment of ailments including neurological diseases, cough, cold & flu, sexual problems, feminine problems, and metabolic diseases. Herbal remedies are used to maintain health and systemic balance, of body functions without sedation and side effects.

In 2015, La Political de Attention Integral a la Saluda Indigene de FUNASA of Brazil promoted traditional systems of health of indigenous communities. Similarly, the government has recognized homeopathic medicines as a medical specialty and included it in the National Health System. Brazil is currently home to around 12,000 homeopathic physicians and 300 homeopathic pharmacists.

As per the World Health Organization (WHO), around 60% of the world’s population is reliant on herbal medicines for primary health care needs. In developing countries, this number accounts for up to 80%. Around 75% of such sales are made through direct user-pharmacy contacts. The growing trend of online pharmacies and mail-on-order purchases drives the demand for self-medication.

The global geriatric population is rapidly expanding with higher life expectancy rates. According to the World Bank, in 1990, the average mortality among geriatric world population was around 6 %, which increased to 9.5% in 2020. The prevalence of chronic diseases associated with an aging population portrays the need for effective medications.

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-2722

Key Takeaways from Protein A Resin Study:

Demand for Chinese medicines is expected to grow at 8.2% CAGR through 2031, owing to investments into promotion of traditional Chinese medicine.
Retail pharmacies are projected to capture over 23% of the global market by 2031. This is attributed to availability of consumer health products.
Europe is the largest revenue-generating region for herbal medicinal products, with Germany accounting for nearly 18% of the regional market in 2031.
China holds the leading position in East Asia, and is expected to account for over 49% of the market in 2031.
South Asia is the third most lucrative market with India accounting for over 74% of the share in 2031.
Competitive Landscape

Manufacturers of herbal medicine are primarily aiming to carry out strategic expansions and filing patents to consolidate growth in a competitive market.
For Instance, In Oct 2020, the Arkopharma SA filled a patent for the Arkodigest® No Reflux 100% natural composition to improve digestion.
In November 2020, Mountain Rose Herbs purchased the Phoenix Industrial Park in Eugene, with 205,000 square feet of operational space and a 12-acre campus, as a part of business expansion strategy to develop it into green space.

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-2722

The key market players covered by FMI include :

  • Blackmores Limited,
  • Sanofi-Aventis Healthcare PTY Ltd.,
  • Arkopharma SA,
  • Nutraceutical Corporation,
  • STADA Arzneimittel AG,
  • Himalaya Global Holdings Ltd,
  • Integria Healthcare,
  • Boiron Group,
  • Young Living Essential Oils,
  • Mountain Rose Herbs

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Vascular Closure Device (VCD) Market will reach US$ 963 million value towards the end of 2022 | FMI

Clinical use of arterial closure devices, also known as vascular closure devices, has experienced a substantial growth over the past decade. With rising incidence of cardiac disorders, new and improved cardiovascular treatments have been developed, which have further propelled the adoption of vascular closure devices (VCDs). According to a recently-published market study by Future Market Insights, the global market for vascular closure devices will expand steadily at a CAGR of 5.9%, and reach US$ 963 million over the forecast period, 2017-2022. Compared to manual compression techniques, vascular closure devices play a key role in lowering undue complications such as bleeding.

However, increasing use of transradial arterial access, the continued requirement for post-procedure bed rest, significant costs, and device deployment complexities are observed as key deterrents for adoption of vascular closure devices. The use of VCDs is also anticipated to be influenced by a significant increase in the number of outpatient PCI procedures and the desire of patients to avoid arterial cut-down procedures. According to the report, hospitals will be the largest end-users of vascular closure devices in the next five years. By the end of 2022, over US$ 600 million revenues are anticipated to be procured globally from the end-use of vascular closure devices in hospitals.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1809

North America to Exhibit Steadfast Adoption of Vascular Closure Devices

A regional analysis provided in the report reveals North America as the largest market for vascular closure devices. The region is anticipated to remain at the forefront of global expansion of vascular closure devices market through 2022. Robust healthcare marketplaces in the US, coupled with consumer lifestyles that have surged the incidence of cardiac disorders, will continue to boost North America’s presence in the global vascular closure devices market. The report also projects that Asia-Pacific excluding Japan (APEJ) region will register fastest growth in its vascular closure devices market, and rake over US$ 145 million by the end of 2022.

Clip-based VCDs to Register 6% CAGR through 2022

A key insight from the report reveals that the demand for clip-based vascular closure devices will be relatively higher than compression devices and haemostasis pads. Despite the latter being top-selling products in the global vascular closure devices market, clip-based VCDs are expected to outpace them in terms of demand over the next five years. From medical standpoint, many surgeons prefer VCDs designed with active approximators that can physically close the arteriotomy by using nitinol clips. These metallic clips can also restrict MRI scanners from capturing the unnecessary structures which are immediately adjacent to the arteriotomy. These clip-based VCDs can boost procedural efficiency as well as post-procedural diagnostics for a wide range of cardiovascular treatments.

Companies to Watch

Companies namely, Abbott Laboratories, Terumo Corporation, Cardinal Health, Inc., Medtronic plc, Cardiva Medical, Inc., Arstasis, Inc., Chitogen, Inc., Marine Polymer Technologies, Inc., Essential Medical, Inc., Scion Cardio-Vascular, Inc., Morris Innovative, Inc., Tricol Biomedical, Inc., Vascular Closure Systems, Inc., and TZ Medical, Inc. are profiled in the report as key players in the global vascular closure devices market. In the near future, several manufacturers of vascular closure devices will be focusing on reducing the existing drawbacks of using VCDs, which include extended hospitalisation, high morbidity risks, and the need for administering antibiotics. Some companies will also be focusing on advancing their umbrella on VCD technologies and improving the quality of life for patients being treated through vascular closure devices.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1809

Market Taxonomy The taxonomy of global vascular closure device market has been concisely illustrated in the table below:

Region

  • North America
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA

Product Type

  • Haemostasis Pads
  • Compression Devices
  • Clip
  • Plug
  • Suture
  • Others

End User

  • Hospitals
  • Ambulatory Surgical Centres
  • Independent Catheterisation Labs

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Microscope Digital Cameras Market to reach a value of around US$ 1.2 Billion by the end of 2027 | FMI

Valuable insights on the global scenario of microscope digital cameras have been presented systematically in a recently carried out research on microscope digital cameras market by Future market Insights in its new publication titled “Microscope Digital Cameras: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)”. This research focusses on key players, trends, growth drivers, opportunities, developments and restraints across several key geographies of North America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Latin America, Japan and Middle East and Africa (MEA). On the basis of a structured research process and taking into consideration the past and present scenario, forecasts are provided in the research report from the period 2017 to 2027, a ten year forecast model, across each and every segment of the market.

Global Microscope Digital Cameras Market: Competition Analysis

The global microscope digital cameras market has profiled key players such as Danaher Corporation, Nikon Corporation, Roper Technologies, Inc., Carl Zeiss AG, Olympus Corporation, Hamamatsu Photonics K.K, Basler AG, Guangzhou Micro-shot Technology Co., Ltd., BMS microscopes bv., and Euromex Microscopen bv.

Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3523

Global Microscope Digital Cameras Market: Forecast Highlights

According to the insightful market survey on microscope digital cameras, the global microscope digital cameras market is anticipated to grow at a high pace to register a robust 9.2% CAGR during the assessment period. During the 2017-2027 period, the global market is estimated to reach a market evaluation of about US$ 1.2 Bn by the end of 2027.

Global Microscope Digital Cameras Market: Segmental Insights

Global microscope digital cameras market is segmented by product type (biological microscope cameras, industrial microscope cameras), by sensor type (CMOS, CCD), by mount type (C mount, eyepiece mount/ocular mount), by end user (hospitals, research laboratories, pharmaceutical and biotechnology industries, clinics) and by region.

  • North America regionshows high lucrativeness and is expected to dominate the global microscope digital cameras market during the forecast period with respect to high market valuation. This region is estimated to grow at a stellar growth rate to reach a valuation of about US$ 353.3 Mn by 2027 end. Japan region is expected to grow at the highest rate, a shade higher than North America to register a 10.3% CAGR throughout the forecast period
  • Biological microscope cameras segment by product type, is projected to register a higher CAGR of 9.3% during the forecast period and is more likely to lead the global market by product type in terms of high market value
  • By mount type, C mount segment shows high potential as it grows at a comparatively high rate to reach a 9.4% CAGR and is likely to show dominance over eyepiece mount/ ocular mount segment. The C mount segment shows a market value almost seven times that of the eyepiece mount/ ocular mount segment
  • The CCD segment by sensor typeis expected to lead the market with a high value share. The CMOS segment shows high growth rate to register a stellar CAGR of 11.3% throughout the assessment period
  • By end user, research laboratories (clinical and non-clinical) segment dominates the global market with a valuation of about US$ 645.7 Mn in 2027, growing at a robust growth rate. With respect to growth rate, the pharmaceutical and biotechnology industries segment is projected to register the highest CAGR of 9.7% during the period of forecast 2017-2027

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3523

Global Microscope Digital Cameras Market: Dynamics

Various factors favour the growth of the global microscope digital cameras market and the impact of these factors changes from region to region. Diverse application of microscope imaging technology, rising preference for CMOS and CCD, increasing penetration of international players through mergers, growing partnerships for direct distribution, higher spending on academic research along with focus on digital pathology, emergence of digitalization in the life science research, rising demand for microscopy cameras in scientific applications, new product innovations and launches, advancements in microscope digital cameras and rising laboratory automation are supporting the growth of the global microscope digital cameras market. However, factors such as premium pricing limiting market penetration ability, limited manufacturing facilities for microscope cameras, high equipment cost and entry barriers for small players to enter the consolidated market are posing growth restraints to the growth of the global microscope digital cameras market.

Market Taxonomy By Product Type

  • Biological Microscope cameras
  • Industrial Microscope Cameras

By Sensor Type

  • CMOS
  • CCD

By Mount Type

  • C Mount
  • Eyepiece Mount/Ocular Mount

By End User

  • Hospitals
  • Research laboratories
  • Pharmaceutical and Biotechnology Industries
  • Clinics

By Region

  • North America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Latin America
  • MEA

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Competent Cells Market is estimated to exceed US$ 2,000 Million in revenues by 2022-end

A latest research study published by Future Market Insights (FMI) projects the global competent cells market to register an impressive 8.1% CAGR throughout the forecast period 2017 to 2022. The global market for competent cells is estimated to exceed US$ 2,000 Mn in revenues by 2022-end.

Competent Cells Available in the Market in Ready-to-use Formats

Preparations of competent cells, along with other methods of transformation, have been continuously improvised, since the development of E. coli’s artificial transformation with the help of electroporation and chemicals. Currently, various competent cells are available in the market in ready-to-use formats for propagating cloned plasmids in the experiments of molecular biology. These competent cells are prepared for different transformation procedures, genotypes, packaging, and transformation efficiencies.

With the advent of new technologies, several advancements have been witnessed in the molecular cloning research. Over the past few years, the recombinant proteins and molecular cloned products have experienced a robust commercial demand, thereby driving adoption of competent cells. However, adoption of competent cells is witnessing strong barriers on the back of increasing consolidation of the market, and huge cost of kits related to competent cells.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-5061

Academic Research Institutes to Remain Largest End-users of Competent Cells

Academic research institutes are anticipated to remain the largest end-users of competent cells throughout the forecast period. Sales of competent cells in academic research institutes are projected to exhibit an impressive expansion to account for nearly half revenue share of the market during 2017 to 2022. However, sales of competent cells in pharmaceutical & biotechnology companies are expected to register the fastest expansion through 2022. Contract research organisations are expected to be the least lucrative end-users of competent cells in the global market.

Competent cells are expected to find the largest application in cloning during 2017 to 2022. Governments across the globe are providing tremendous support and funding for research and development activities associated with cloning. Revenues from sales of competent cells for application in cloning are estimated to account for over half revenue share of the market during the forecast period. Sales of competent cells for application in protein expression are expected to register the highest CAGR through 2022.

North America will Continue to be Largest Market for Competent Cells

In terms of revenues, North America is anticipated to remain the largest market for competent cells, with sales estimated to exceed US$ 750 Mn in revenues by 2022-end. Huge investments in research and development activities associated with competent cells is driving the market in North America. In addition, the market in Europe is estimated to create an absolute $ opportunity of nearly US$ 200 Mn between 2017 and 2022.

On the basis of product type, although chemically competent cells will continue to be sought-after in the market, sales of electrocompetent cells are projected to register a relatively faster expansion through 2022. Growing demand for electrocompetent cells can be mainly attributed to their provision of high transformation efficiencies, making them suitable for several molecular biology applications, for example – construction of gene banks, or, generation of cDNA libraries. Revenues from sales of electrocompetent cells are projected to account for nearly one-third share of the market over the forecast period.

Leading Market Players focusing on Increasing their Product Portfolio

Global leading players in the competent cells market are focusing on increasing their product folio, in a bid to gain a competitive edge in the market. Key players listed in FMI’s report on the global competent cells market include:

  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • Genescript Biotech Corporation
  • Illumina Inc.
  • Merck & Co. Inc.
  • New England Biolabs Inc.
  • OriGene Technologies Inc.
  • QIAGEN N.V.
  • Thermo Fischer Scientific Inc.
  • Zymo Research Corporation.

 Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-5061

Market Taxonomy Region

  • North America
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA

Product Type

  • Chemically Competent Cells
  • Electrocompetent Cells

End User

  • Academic Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations

Application

  • Cloning
  • Protein Expression
  • Other Applications

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Plasma Separation Tubes Market is estimated to reach US$ 874.6 Million by 2031

[250 Pages Report] According to a recent study by Future Market Insights (FMI), sales in the plasma separation tubes market are expected to top US$ 466.6 Mn in 2021. The market is likely to register a CAGR of over 6.5% during the forecast period, from 2021 to 2031.

Plasma present in a human blood is one of the convenient sources which can circulate biomarkers. The antibodies, antigens and foreign nucleic acid present in plasma, help to diagnose a variety of serious infectious diseases including cancer, Alzheimer’s, and those caused due to Zika or Ebola virus during outbreaks.

Data Points Market Insights
Plasma Seperation Tubes Market Value 2020 US$ 443.5 Mn
Plasma Seperation Tubes Market Estimated Value 2021 US$ 466.6 Mn
CAGR 2021-2031 6.5%

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-7292

As per The Lancet’s 2020 report on the global burden of diseases 2019, which was led by the Institute of Health Metrics & Evaluation analyzed more than 286 causes of death and stated that around 204 countries across the globe were affected by nearly 369 kinds of diseases and injuries associated with more than 80 risk factors. Global crisis due to chronic diseases and related risk factors have left a large number of population at a higher risk and vulnerable to acute health emergencies like in COVID-19 cases.

High prevalence of diseases together with growing researches into development of novel products like miniaturized versions of plasma separation tubes is expected to give opportunity for the market players to invest and grow in the future.

Plasma separation tubes products portfolio involves EDTA tubes, lithium heparin tubes and sodium heparin tubes. There is a growing demand from healthcare sector for advances in developing systems which can help plasma separation from blood without affecting its yield or purity while avoiding variability due to hemolysis.

The centrifugation process thus plays an important role to alleviate such issues. This in turn has increased the demand for tubes for plasma separation.  The increasing ageing population world-wide together with improved healthcare infrastructure, rising investment towards healthcare expansion by governments, and investments in research and developments are expected to stimulate growth in the plasma separation tube market.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-7292

Key takeaways from Plasma Separation Tubes Market study

  • By product, EDTA tubes comprise the most lucrative segment. Demand for EDTA tubes will grow at a CAGR of more than 7.2% over 2021-2031.
  • By material, PET/Plastic tubes will lead the market in the forecast period growing at CAGR of 6.7%.
  • By application, routine chemistry will dominate the market with more than 34% of the share in 2031.
  • By end user, diagnostic laboratories segment is leading the market and expected to hold more than 46% of revenue share over the forecast period.
  • Europe will dominate the global plasma separation tubes market in terms of revenue in 2021, followed by East Asia.
  • China holds lead in in East Asia and is expected to account for nearly 66% of market share by 2031.

“With competition expected to soar in the coming years, market players are expected to shift focus towards expansion of their portfolio. Besides investment in advanced product development, some are expected to emphasize on mergers and acquisitions to strengthen their global footprint,” said a FMI analyst.

Who is winning?

Some of the leading manufacturers of plasma separation tubes are focusing on innovative and strong product portfolio management, increased investment in research and development, online & offline engagement and partnerships as growth strategies, in order to enhance their market presence.

  • In June 2018, Poly Medicure acquired Plan 1 Health S.R.L., one of the prominent medical device player operating in Italy. This acquisition will help company to expand its geographical reach as well as enhance its portfolio in the medical device industry region. Further, as per agreement, Plan 1 Health S.R. L. will now operate as a subsidiary of Poly Medicure B.V, and indirect subsidiary of Poly Medicure Limited.
  • In June 2021, Sekisui Medical acquired Veredus Laboratories Pte.Ltd., a testing company based out of Singapore. This acquisition enabled the company to strengthen their presence in the Asian economies
  • In March 2018, BD upgraded its instruction for its BD Vacutainer tubes as a part of its quality process, which ensures appropriate use of these tubes
  • In Oct 2018, Aptaca introduced VacuAptaca series for its vacuum collection blood and urine devices

The key market players covered includes Becton, Dickinson, & Company, Greiner Bio-One GmbH, Guangzhou Improve Medical Instruments Co.,Ltd, AB Medical, Inc., SARSTEDT AG & Co. KG, Cardinal Health, Poly Medicure Ltd, FL Medical , InterVac Technology, CHENGDU RICH SCIENCE INDUSTRY CO., LTD., Zhejiang Gongdong Medical Technology Co., Ltd., Aptaca Spa., Hindustan syringes & Medical Devices.

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global plasma separation tubes market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on plasma separation tubes segment based on Product (EDTA tubes, lithium heparin tubes and sodium heparin tubes), by material (PET/Plastic and glass), by application (routine chemistry, serology & immunology, blood typing, blood sugar assay , molecular genetics, others), end user (diagnostic laboratories, hospitals & clinics, research & academic institutes, veterinary hospitals & clinics) across seven major regions.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-7292

Plasma separation tubes Market by Category

Product

  • EDTA Tubes
  • Lithium Heparin Tubes
  • Sodium Heparin Tubes

Material

  • PET/Plastic
  • Glass

Application

  • Routine Chemistry
  • Serology & Immunology
  • Blood Typing
  • Blood Sugar Assay
  • Molecular Genetics
  • Others

End User

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Research & Academic Institutes
  • Veterinary Hospitals & Clinics

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Small-Molecule Injectable Market is projected to reach US$ 112.9 Billion by 2031

[270 Pages Report] The global small-molecule injectable market was valued at US$ 55.8 Bn in 2020. Expanding at a 7.3% CAGR, the market valuation is expected to top US$ 112.9 Bn by 2031, finds ESOMAR-certified consulting firm Future Market Insights (FMI) in a recent market analysis.

The COVID-19 pandemic outbreak has sparked efforts to repurpose already-approved medicines for treatment. Several clinical studies are now being conducted on different antiviral medicines and small-molecule injectables that have been utilized in the past to treat diseases including SARS, MERS, HIV/AIDS, and malaria. For instance, Remdesivir was approved by FDA for the treatment of COVID-19 in hospitalized adult and pediatric patients.

This is expected to fuel sales of small-molecule injectables over the forecast period. Besides this, rising prevalence of chronic illnesses especially cancer and cardiovascular diseases across the globe are anticipated to usher developments in the small-molecule injectables market.

Pharmaceutical companies are aiming at production facility expansions to reduce corporate tax rate (in the U.S.), and to expand their footprints in emerging markets such as India and China, where production cost is low as compared to regions such as Europe and North America.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14117

Recent tax reforms in the U.S., which include reduction of the corporate tax rate, have encouraged various large pharmaceutical and biopharmaceutical companies to invest in production facilities.

For example, in July 2020, Pfizer announced its plan to invest around US$ 465.0 million to build a sterile injectable plant in Portage, Michigan. This step is a part of its announcement that it made earlier in 2020 about its plans to invest around US$ 5.0 billion in a U.S.-based capital project due to the recent corporate tax reforms in the country. These developments are indicative of lucrative growth prospects for small-molecule injectable market players.

“Increasing adoption of chemotherapy for cancer treatment is expected to propel the small-molecule injectable market growth. In addition to this, fast track drug approvals will continue spurring demand for small-molecule injectables over the forecast period,” says the FMI Analyst.

Key Takeaways:

  • By product, the analgesics segment is expected to hold 23.9% of the total small-molecule injectable market in 2021, expanding at 8.0% CAGR.
  • In terms of applications, demand for small-molecule injectables in the infectious disease segment is expected to hold 31.7% of the total market share in 2021.
  • By route of administration, the intravenous segment is anticipated to hold 50% of the total market share in 2021.
  • Sales of small-molecule injectables through hospital pharmacies are projected to account for 67.8% of the total market share in 2021.
  • The U.S. is anticipated to dominate the North America small-molecule injectables market, holding 92.4% of the market share.
  • Germany is expected to hold of 21.9% of the Europe small-molecule injectable market share by 2031.
  • Small-molecule injectable market in China is projected to expand at a 9.0% CAGR over the forecast period.
  • Demand for small-molecule injectables in India is forecast to grow at an impressive 11.1% CAGR through 2031.
  • Sales of small-molecule injectables in South Korea and Japan are anticipated to rise at 5.0% and 8.8% respectively.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14117

Competition Landscape

The key market players covered by FMI include Aurobindo Pharma Limited, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., AstraZeneca Plc, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Baxter International, Fresenius Kabi, Cipla Ltd, Mylan N.V., Sanofi S.A, and Dr. Reddy’s Laboratories Ltd.

Leading manufacturers of small-molecule injectables are focusing on strategic collaborations and partnerships to strengthen product portfolios. Manufacturers are also aiming at production facility expansions through acquisitions and mergers to gain a competitive edge in the market. For instance:

  • In September 2020, Aurobindo Pharma USA Inc. acquired commercial operations and three manufacturing facilities in the U.S from Sandoz Inc., USA, and Novartis Division.
  • In May 2020, Novartis AG received FDA approval for first Piqray – the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer.
  • In April 2020, AstraZeneca announced a collaboration with Benevolent AI to use machine learning and artificial intelligence to discover potential new drugs for chronic kidney disease and idiopathic pulmonary fibrosis.

More Insights into the Small-Molecule Injectable Market Report

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global small-molecule injectable market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights into small-molecule injectable market. The market is segmented into five parts based on product (small molecule antibiotics, chemotherapy agents, local and general anesthetics, skeletal muscle relaxants, analgesics, anticoagulants, anticonvulsants, antivirals, anti-histamines/ anti-allergy, and others), application (oncology, pain management, cardiovascular diseases, infectious diseases, CNS diseases, blood disorders, musculoskeletal disorders, and others), route of administration (intravenous (IV), intramuscular (IM), and subcutaneous (SC)) and distribution channel (hospital pharmacies, retail pharmacies, drug stores, and mail order pharmacies) across seven major regions.

Small Molecule Injectable Market by Category

By Product:

  • Small Molecule Antibiotics
  • Chemotherapy Agents
  • Local and General Anaesthetics
  • Skeletal Muscle Relaxants
  • Analgesics
  • Anticoagulants
  • Anticonvulsants
  • Antivirals
  • Anti-histamines/ Anti-allergy
  • Others

By Application:

  • Oncology
  • Pain Management
  • Cardiovascular Diseases
  • Infectious Diseases
  • CNS Diseases
  • Blood Disorders
  • Musculoskeletal Disorders
  • Others

By Route of Administration:

  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous (SC)

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Manometry Systems Market to reaching a valuation of US$ 279.6 Million by 2031

[250 Pages Report] Sales of global manometry systems are expected to reach US$ 157.3 Mn in 2020. As per Future Market Insights, revenues for manometry systems are expected to reach US$ 279.6 Mn, expanding at a 5.4% CAGR over the forecast period (2021-2031).

Rise in number of people aged 65 years and older is expected to be the major factor boosting the growth of the manometry system market. In 2018, According to the U.S. Census Board people older than 65 years represent around 13% of the total population; this percentage is expected to reach 20% by 2031.

Rising cases of constipation, fecal incontinence, anorectal pain, pelvic floor dyssynergia and hirschsprung’s among older population is increasing the adoption of manometry systems. Demand for these systems helps evaluate patients and provides many useful data regarding anorectal function and indicates the prognosis of treatment, particularly in the management of sphincter injuries.

Get Sample Report@  https://www.futuremarketinsights.com/reports/sample/rep-gb-14110

Rising demand for non-invasive equipment is driving the demand for manometry system. These systems are non-invasive diagnostic procedure that can detect pressures and sensation in the anus and rectum. With this, they indicate whether the patient’s pelvic function is normal without incision into the body or removal of tissue and has low risks, and complications.

Further, rising government initiatives and funding supporting the development of product is boosting the demand for manometry system market.  Initiatives undertaken by government to enable and boost the ecosystem for the indigenous medical device industry is also stimulating market growth.

Base Year Value (2020A) US$ 157.3 Mn
Projected year (2031) Market Value US$ 279.6 Mn
CAGR% (2021-2031) 5.4% CAGR

“As demand for manometry systems is rising due to high prevalence of gastrointestinal diseases, key players are engaging in product development that is technologically advanced for faster approvals. This is expected to give the key players a competitive edge in the industry, generating revenues,” says the FMI Analyst

Key Takeaways from Manometry System Market Study

  • By product, system sheath & catheters is expected to account for the largest share of 55.0% in 2021.
  • In terms of portability, stand-alone system will hold for the largest share of 55.4% in 2021 on the back of its enhanced sensitivity to provide accurate diagnosis of condition
  • By end user, hospitals accounted for the largest share of 37.9% in 2021 owing to the rising demand for hospital stay that is short-term and increasing number of gastrointestinal processes.
  • North America is expected to hold largest share of 38.9% in 2021 with the U.S. leading the market during the forecast period.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14110

Who is Winning?

Some of the leading manufacturers of manometry system market are focusing on product launch collaboration and partnership strategies for global expansion objectives, thereby, enhancing their market presence.

Several joint ventures, agreements, and loan licensing procedures have influenced the market. The government of developing economies has taken several reforms to develop the market by regulating it to bring out more transparency and by allowing foreign investments in the industry.

New Product launches & approvals have emerged as key growth strategy adopted by the leading players in the manometry system market. Followed by this, acquisition was the second most key strategy adopted by the industry players. By adopting these strategies, it helped the company to expand their regional presence as well as product offerings.

For instance,

  • In October 2021, “UROTECH GmbH subsidiary of Medi-Globe Group’s provided detailed information on a new clinical study for using the Magnetic Black-Star® (MBS) in paediatric urology. The MBS was an innovative product of the UROTECH GmbH, which is used in stent placement as well as stent removal of children by without performing the surgeries using the stent’ magnetic tip.”
  • In May 2020, RMS Medical Devices, proudly announced it’s the acquisition of QUICKORE products for BENELUX. With this new acquisition, RMS Medical Devices adds another premium technology to its Radiology portfolio.
  • In October 2020, LABORIE Medical Technologies enters into strategic partnership with Urotronic to support regulatory approval of Optilume™, a drug-coated balloon (DCB) technology for use in urethral strictures and benign prostatic hyperplasia (BPH).
  • In August 2021, Medtronic Announced the FDA Approval of Next-Gen TAVR System for the treatment of symptomatic severe aortic stenosis. Next-Gen TAVR System is a self-expanding transcatheter aortic valve replacement, which is designed to enhance ease-of-use and predictable valve deployment throughout the procedure.

The key market players covered by FMI include EB Neuro S.p.A, MEDSPIRA, Medtronic, Medica S.p.A., RMS Medical Devices, MARQUAT Génie Biomédical, Diversatek Inc., Dentsleeve International Ltd., LABORIE, Prometheus Group, Smart Medical Group, Synectics Medical Limited, Medovations Inc., Sierra Scientific, and Urotech Gmbh.

Manometry System by Category

Product:

  • Anorectal Manometry System
  • Anorectal Manometry System Software
  • Anorectal Manometry System Sheath & Catheters

Portability:

  • Stand Alone System
  • Portable System

End User:

  • Hospitals
  • Diagnostic Centers
  • Speciality Clinics
  • Academic Research Institutes

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Nasal Antihistamines Market is anticipated to total US$ 3.0 Billion by 2031 | FMI

According to a recent study by Future Market Insights (FMI), the nasal antihistamines market is expected to witness steady growth during the forecast period. The market valuation is expected to increase from US$ 1.89 Bn in 2020 to over US$ 3.08 Bn by 2031. This reflects a cumulative CAGR of around 3.1% over the forecast period (2021-2031).

Antihistamines are a class of medications that are often used to treat allergy symptoms. These medications are used to treat problems caused by an excess of histamine, a substance produced by the immune system. People who are allergic to pollen and other allergens are the most prevalent users of antihistamines. Sneezing, congestion, and itchy, runny nose can all be relieved with antihistamine sprays. They are available by prescription and include azelastine (Astelin, Astepro) and olopatadine (Patanase).

The global burden of respiratory diseases such as allergic rhinitis, chronic obstructive pulmonary disease, asthma has increased rapidly in the last three decades. In an article published in NCBI, it was reported that around 20–30 % of the Indian population suffers from allergic rhinitis and that 15 % develop asthma.

Due to this growing burden, there has been an increased adoption rate of nasal antihistamines in the form of nasal sprays and nasal drops, globally. The nasal antihistamines provide rapid and effective relief from the symptoms of allergic rhinitis. Thus, the growing number of allergic rhinitis cases will propel the growth of the nasal antihistamines market in the future.

Advancements in the field of nasal drug delivery have enabled the establishment of several non-invasive approaches for treatment. Various new products such as metered dose delivery systems, innovative odorless powders and sprays, preservative-free nasal sprays and others are key drivers that will expand this industry in the forecast period.

FDA approvals of various nasal sprays to switch from prescription to OTC use has led to increased independence concerning self-administration of drugs, amongst patients who suffer from allergic rhinitis. Various additions by the manufacturers to the already available product lines, especially for AR are some of the techniques used by the manufacturers to increase product penetration amongst the population.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-13708

New product launches & approvals have emerged as key growth strategies adopted by the leading players in the nasal antihistamines market. Followed by this, the acquisition was the second most key strategy adopted by the industry players. By adopting these strategies, it helped the company to expand their regional presence as well as product offerings.

For instance, In December 2020, GlaxoSmithKline launched Otrivin Breathe clean, a saline wash with the moisturizing benefit of natural glycerine as a product for the symptomatic relief of allergic rhinitis.

Such developments not only strengthens the company’s existing portfolio but also help to increase their presence at the regional as well as global level, and helps companies to sustain the increasing competitive pressure.

Key Takeaways from Nasal Antihistamines Market Study

  • By pProduct, nasal sprays accounted for the largest share of 89.0% in 2021 and are expected to continue to grow at the same trend during the forecast period.
  • By age group, adults accounted for the largest share in 2021 of the nasal antihistamines market and are expected to continue to grow at the same trend during the forecast period.
  • By distribution channel, the retail pharmacies segment is expected to account for the largest share of 41.0% in 2021 of the nasal antihistamines market and is expected to continue to grow at the same trend during the forecast period.
  • By region, East Asia held the largest share of 23.0% in 2021 of the nasal antihistamines market. The growing awareness regarding allergies and developing healthcare infrastructure are some of the factors that fuel the high market share of this region.

Who is Winning?

Some of the leading manufacturers of the nasal antihistamines market are focusing on product launch collaboration and partnership strategies for global expansion objectives, thereby, enhancing their market presence.

  • In April 2021, Merck & Co. acquired Pandion Therapeutics, Inc which is a U.S. based clinical-stage biotechnology company for US $ 1.85 Bn. With this acquisition, Merck strategizes to identify and secure candidates with differentiated and potentially found characteristics for the clinical trials that would be required for their new product launches. This will ensure smooth conduction of clinical trials and thus help the company to expand their business.
  • In April 2020, Cipla receives final approval for a generic version of Proventil® HFA Inhalation Aerosol, from the United States FDA. With this approval, the company strengthened their presence in the US pharmaceutical market

The key market players covered by FMI include Bayer Healthcare LLC, Novartis International AG, Cipla, Glenmark Pharmaceuticals, GlaxoSmithKline, Sun Pharmaceuticals, Merck & Co., Centaur Pharmaceuticals, Viatris (Meda Pharmaceuticals), Proctor & Gamble, Ascend Laboratories LLC (Alkem Laboratories), J Pharmaceuticals, Alitair Pharmaceuticals and Sato Pharmaceuticals.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-13708

Nasal antihistamines by Category Product:

  • Nasal Spray
  • Nasal Drops

Age Group:

  • Adult
  • Pediatric

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Stores

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs